2322 PCA3 VARIABILITY IN MEN WITH VERY LOW RISK PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Markers1 Apr 20112322 PCA3 VARIABILITY IN MEN WITH VERY LOW RISK PROSTATE CANCER Sergey Shikanov, Gautam Jayram, Michael S. McGuire, and Charles B. Brendler Sergey ShikanovSergey Shikanov Chicago, IL More articles by this author , Gautam JayramGautam Jayram Chicago, IL More articles by this author , Michael S. McGuireMichael S. McGuire Evanston, IL More articles by this author , and Charles B. BrendlerCharles B. Brendler Evanston, IL More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.2569AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Urinary PCA3 is considered a specific marker of prostate cancer tumor volume. We hypothesized that it will remain stable in patients with minimal disease without treatment. METHODS 41 men with very low risk prostate cancer were enrolled in an IRB-approved active surveillance protocol. All men had clinical stage T1c, Gleason score 6, positive cores ≤3 and involvement of no positive core ≥50%. Urinary PCA3 was measured at enrollment and at 6 months. We assessed percent change ([enrollment PCA3–6 months PCA3 /enrollment PCA3]x100%) and proportion of positive tests (PCA3 score >35) at both time points. None of the patients had evidence of clinical progression during the observation period. RESULTS Table 1 summarizes the cohort parameters. Median %PCA3 change was only 3%, and 46% of patients had positive PCA3 score both at enrollment and 6 months. However, compared to the enrollment PCA3 score, at 6 months the PCA3 score varied by more than 25% in 58% (n=24) and by more than 50% in 31% (n=13) of patients(Figure 1). When comparing PSA changes in the same population, PSA varied by more than 25% in only 41% (n=17) and by more than 50% in 7% (n=3) of patients. Table 1. Cohort parameters, n=41 Positive cores 1 22(54%) 2 15(36%) 3 4(10%) Max.% of core involvement 5(4–10) Enrollment PCA3 31(19–69) 6 month PCA3 34(16–59) % change PCA3 3(−31–35) Enrollment PCA3 > 35 19(46%) 6 moths PCA3 > 35 19(46%) Enrollment PSA, ng/ml 4.2(3.0–5.3) 6 months PSA, ng/ml 3.3(2.9–5.5) % change PSA 1(−18–25) Continuous data presented as median (0.25–0.75 quartile range), categorical data presented as count (of total). CONCLUSIONS While urinary PCA3 scores on average change only slightly over 6 months in clinically stable men with very low risk prostate cancer, PCA3 scores vary significantly among individual patients. Given this variability, the usefulness of PCA3 in guiding treatment recommendations for the individual patient remains uncertain. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e931 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Sergey Shikanov Chicago, IL More articles by this author Gautam Jayram Chicago, IL More articles by this author Michael S. McGuire Evanston, IL More articles by this author Charles B. Brendler Evanston, IL More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...